STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive: Importantly, JNJ-165 (2 μM) was shown to significantly inhibit the phosphorylation of BCR/ABL and lower STAT5 and STAT3 kinase activity in both primary CML cells and primary CML cells harboring E255K, an Imatinib-resistant mutation [29, 30] (Figure 3C).